

# STATE OF NEW YORK

6927

2025-2026 Regular Sessions

## IN ASSEMBLY

March 18, 2025

Introduced by M. of A. SIMONE -- read once and referred to the Committee on Higher Education

AN ACT to amend the education law and the public health law, in relation to prescription labels for mifepristone, misoprostol, gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy for treatment of gender dysphoria

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

1 Section 1. Paragraph b-1 of subdivision 1 of section 6807 of the  
2 education law, as added by chapter 7 of the laws of 2025, is amended to  
3 read as follows:

4 b-1. Notwithstanding paragraph b of this section, the prescription  
5 label for mifepristone, misoprostol, [~~and their generic alternatives~~]  
6 gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic  
7 steroids, alpha reductase inhibitors, progestins, or drug classes for  
8 hormone replacement therapy for treatment of gender dysphoria, may  
9 include the name or address of the dispensing health care practice  
10 instead of the name of the dispenser.

11 § 2. Subdivision 1-a of section 6810 of the education law, as added by  
12 chapter 7 of the laws of 2025, is amended to read as follows:

13 1-a. Notwithstanding subdivision one of this section, at the  
14 prescriber's request, the prescription label for mifepristone, misopros-  
15 tol, [~~and their generic alternatives~~] gonadotropin-releasing hormone  
16 agonists, pubertal suppressants, anabolic steroids, alpha reductase  
17 inhibitors, progestins, or drug classes for hormone replacement therapy  
18 for treatment of gender dysphoria, may include the name of the prescrib-  
19 ing health care practice instead of the name of the prescriber.

20 § 3. The public health law is amended by adding a new section 280-d to  
21 read as follows:

EXPLANATION--Matter in italics (underscored) is new; matter in brackets  
[-] is old law to be omitted.

LBD10852-01-5

1     § 280-d. Patient notification of prescription label change. A health  
2 care prescriber shall inform the patient if such prescriber has included  
3 or has requested to include the name or address of the prescribing  
4 health care practice instead of the name of such prescriber on the  
5 prescription label when prescribing mifepristone, misoprostol, gonado-  
6 tropin-releasing hormone agonists, pubertal suppressants, anabolic ster-  
7 oids, alpha reductase inhibitors, progestins, or drug classes for  
8 hormone replacement therapy for treatment of gender dysphoria.

9     § 4. This act shall take effect immediately.